CAJ | 학술논문

互联网药品经营出现于上世纪末，国外形成了多元主义、法团主义和国家主义三类监管模式。我国目前有第三方、B2B、B2C等经营类型，新业态不断涌现，然而安全状况不容乐观。现有监管制度存在立法位阶偏低、内容缺失、主体混杂和手段单一等问题。完全放开或彻底禁止互联网药品经营都不符合实际，应采取折衷的互联网药品经营监管模式。建议利用修订《药品管理法》和开展互联网药品经营第三方电子商务平台试点的契机，重构我国互联网药品监管制度的定位、理念、路径和手段。
호련망약품경영출현우상세기말，국외형성료다원주의、법단주의화국가주의삼류감관모식。아국목전유제삼방、B2B、B2C등경영류형，신업태불단용현，연이안전상황불용악관。현유감관제도존재입법위계편저、내용결실、주체혼잡화수단단일등문제。완전방개혹철저금지호련망약품경영도불부합실제，응채취절충적호련망약품경영감관모식。건의이용수정《약품관리법》화개전호련망약품경영제삼방전자상무평태시점적계궤，중구아국호련망약품감관제도적정위、이념、로경화수단。
Online drug sale occurred at the middle of 1990s, forming three regulatory models, namely, pluralism, corporatism and statism, in other countries. While in China, there are three main business types, including third-party e-commerce platform, B2B and B2C, with some other new types emerging. However, online drug regulation and relevant safety record are not optimistic. The current regulation has four defects, which are low legislative order, lack of core content, mixed legal subjects and single enforcement measure. Online drug sale can be neither completely opened nor banned, but to take a compromised regulation path. Therefore, it is suggested that in this chance of the Drug Administration Law amendment as well as the implementation of third-party e-commerce platform of online drug sale, the positioning, ideology, path and means of China’s online drug sale regulatory institution should be reconstructed.